Physician profile
Niraj Kothari
NPI 1306188321
$713.33
in general payments reported to CMS, 2019-2025
8 companies · $415 in 2025
The $415 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $17.52 · 2022: $82.96 · 2023: $37.12 · 2024: $161 · 2025: $415.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $613.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $612.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $189.37 | 2025 | Xphozah 30 Mg, Ibsrela |
| Kerecis Limited | $154.65 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Astrazeneca Pharmaceuticals Lp | $124.34 | 2024 | Lokelma |
| W. L. Gore & Associates, INC. | $107.37 | 2024-2025 | Gore-Tex Vascular Graft, Gore Acuseal Vascular Graft, Gore Viabahn Vbx Balloon Expandable Endo |
| Alexion Pharmaceuticals, INC. | $82.96 | 2022 | |
| Fresenius USA Marketing, INC. | $23.63 | 2023 | Velphoro |
| Akebia Therapeutics INC | $17.52 | 2020 | |
| Astellas Pharma US INC | $13.49 | 2023 | Veozah |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Niraj Kothari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.